| abstract |
The compounds are potent inhibitors of cdk-kinases and growth factor-mediated kinases. They have the general formula wherein R 2, R 7, R 13, R 14 and R 15 are independently hydrogen or (unsubstituted) lower alkyl, (unsubstituted) lower alkenyl, (unsubstituted) lower alkynyl or (unsubstituted) ; R5 is halogen, cyano, nitro, -R9, -NR9R10 or -OR9; R6 is halogen, cyano, nitro, -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9R10, -NR9COR10, (un) substituted lower alkenyl or (un) substituted lower alkynyl; R8 is -CO2R13, -COR13, -CONR13R14, -CSNR13R14, -C (NR13) NR14R15, -SO3R13, -SO2R13, -SO2NR13R14, -PO3R13R14, -POR13R14, -PO (NR13R14) 2; R9 and R10 are independently hydrogen or (un) substituted lower alkyl; R11 is a heteroaryl or heterocyclic group; R12 is a cycloalkyl, heterocyclic, aryl or heteroaryl group and n has the value of 0, 1, 2 or 3. The compounds and their pharmaceutical compositions are used in the treatment of cell proliferative disorders, for example cancer and restenosis. |